An exclusive licensing agreement has been reached between Jazz Pharmaceuticals (Nasdaq: JAZZ) and Zymeworks (NYSE: ZYME), granting the former extensive development and commercialization rights to zanidatamab.
The deal includes all indications and most markets, excluding only certain Asia-Pacific territories previously licensed by Zymeworks.
For its part, Zymeworks will get $50 million right away, and potentially an additional $325 million, if Jazz opts to continue the collaboration past the top-line readout from the HERIZON-BTC-01 study.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze